Drug Patents owned by Organon

1. List of Implanon drug patents

IMPLANON's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant
Aug, 2026

(3 years from now)

US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(4 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(4 years from now)

US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(7 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

IMPLANON family patents

13

European Union

7

United States

4

South Africa

4

Australia

4

Norway

4

Argentina

4

Brazil

4

Korea, Republic of

4

China

4

Japan

4

Canada

4

New Zealand

3

Mexico

3

Hong Kong

3

Russia

3

Portugal

3

Spain

3

Peru

3

Taiwan, Province of China

3

Ukraine

2

Denmark

2

Slovenia

2

Poland

1

Israel

1

Austria

1

Egypt

1

Lithuania

1

Hungary

1

Latvia

1

Germany

1

Croatia

1

Cyprus

1

Malaysia

1

Ecuador

2. List of Singulair drug patents

SINGULAIR's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830 ORGANON Granule formation
Oct, 2022

(5 months ago)

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 26 July, 2002

Treatment: NA

Dosage: GRANULE;ORAL

How can I launch a generic of SINGULAIR before it's patent expiration?
More Information on Dosage

SINGULAIR family patents

3

United States

2

Canada

1

South Africa

1

Denmark

1

Austria

1

Mexico

1

Australia

1

Egypt

1

Slovenia

1

Hungary

1

Norway

1

Germany

1

Croatia

1

Brazil

1

Portugal

1

Cyprus

1

Malaysia

1

Spain

1

Peru

1

Korea, Republic of

1

China

1

Ecuador

1

Japan

1

European Union

3. List of Zetia drug patents

ZETIA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7030106 ORGANON Sterol absorption inhibitor compositions
Jan, 2022

(1 year, 2 months ago)

US7030106

(Pediatric)

ORGANON Sterol absorption inhibitor compositions
Jul, 2022

(8 months ago)

US7612058 ORGANON Methods for inhibiting sterol absorption
Oct, 2025

(2 years from now)

US7612058

(Pediatric)

ORGANON Methods for inhibiting sterol absorption
Apr, 2026

(3 years from now)

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...

Dosage: TABLET;ORAL

How can I launch a generic of ZETIA before it's patent expiration?
More Information on Dosage

ZETIA family patents

37

United States

17

European Union

12

Japan

9

Australia

9

Canada

8

Denmark

8

Austria

8

Hong Kong

8

Slovenia

8

Germany

8

Argentina

8

Portugal

8

Spain

8

China

7

Mexico

6

Hungary

6

Norway

6

Cyprus

6

Korea, Republic of

6

Ecuador

5

South Africa

5

Slovakia

5

Russia

5

Brazil

5

Czech Republic

5

New Zealand

4

Poland

4

Taiwan, Province of China

2

Israel

1

Turkey

1

Morocco

YU

1

Yugoslavia

1

Malaysia

1

Peru

1

Chile

1

RS

1

Georgia

1

ME

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic